1627580-64-6
Chemical Structure
MOTS-c (human)
- CAS. Nr.: 1627580-64-6
- Formula:C101H152N28O22S2
- Molecular Weight:2174.59
IUPAC Name: (2S,5S,8S,11S,17S,20S)-20-((5S,8S,11S,14S)-11-((1H-indol-3-yl)methyl)-5-amino-14-(3-amino-3-oxopropyl)-8-(3-guanidinopropyl)-6,9,12-trioxo-2-thia-7,10,13-triazapentadecan-15-amido)-5-benzyl-8-((S)-sec-butyl)-1-((S)-2-(((6S,9S,12S,15S)-1,20-diamino-12-(4-aminobutyl)-6-carboxy-1,20-diimino-9-isobutyl-8,11,14-trioxo-2,7,10,13,19-pentaazaicosan-15-yl)carbamoyl)pyrrolidin-1-yl)-2,11-bis(4-hydroxybenzyl)-17-(2-(methylthio)ethyl)-1,4,7,10,13,16,19-heptaoxo-3,6,9,12,15,18-hexaazatricosan-23-oic acid
SMILES: O=C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC1=CNC2=CC=CC=C12)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCSC)C(NCC(N[C@@H](CC3=CC=C(C=C3)O)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC4=CC=CC=C4)C(N[C@@H](CC5=CC=C(C=C5)O)C(N6[C@@H](CCC6)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CCSC)N
Biological Activity: MOTS-c (human) is a mitochondrial-derived peptide that modulates the AMPK/PGC-1α pathway to enhance insulin sensitivity. MOTS-c (human) inhibits the folate cycle and de novo purine synthesis, increases AICAR levels to activate AMPK, and then regulates the Nrf2/Keap1 antioxidant pathway and inhibits the NF-κB inflammatory pathway, while promoting mitochondrial biogenesis and energy metabolism. MOTS-c (human) has the effects of improving glucose and lipid metabolism, anti-oxidative stress, anti-inflammatory and neuroprotection, and can be used in the study of type 2 diabetes, traumatic brain injury, inflammatory diseases and aging-related metabolic disorders[1][2][3][4].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
MOTS-c (human) | 99.90% | MOTS-c (human) is a mitochondrial-derived peptide that modulates the AMPK/PGC-1α pathway to enhance insulin sensitivity. MOTS-c (human) inhibits the folate cycle and de novo purine synthesis, increases AICAR levels to activate AMPK, and then regulates the Nrf2/Keap1 antioxidant pathway and inhibits the NF-κB inflammatory pathway, while promoting mitochondrial biogenesis and energy metabolism. MOTS-c (human) has the effects of improving glucose and lipid metabolism, anti-oxidative stress, anti-inflammatory and neuroprotection, and can be used in the study of type 2 diabetes, traumatic brain injury, inflammatory diseases and aging-related metabolic disorders. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Mohtashami Z, et al. MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases. Int J Mol Sci. 2022 Oct 9;23(19):11991. [Content Brief]
- [2]. Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015 Mar 3;21(3):443-54. [Content Brief]
- [3]. Yin X, et al. The intraperitoneal administration of MOTS-c produces antinociceptive and anti-inflammatory effects through the activation of AMPK pathway in the mouse formalin test. Eur J Pharmacol. 2020 Mar 5;870:172909. [Content Brief]
- [4]. Tang M, et al. The role of MOTS-c-mediated antioxidant defense in aerobic exercise alleviating diabetic myocardial injury. Sci Rep. 2023 Nov 13;13(1):19781. [Content Brief]
